Meeting an un-MET need: Targeting MET in non-small cell lung cancer

類似資料

• The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC
  著者:: Tejas Patil, MD, 等
  出版事項: (2024-02-01)
• Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
  著者:: Sally C.M. Lau, MD, MPH, 等
  出版事項: (2023-10-01)
• Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
  著者:: Li Liu, 等
  出版事項: (2021-06-01)
• Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
  著者:: Leylah M. Drusbosky, 等
  出版事項: (2021-08-01)
• Canadian Consensus Recommendations on the Management of <i>MET</i>-Altered NSCLC
  著者:: Parneet K. Cheema, 等
  出版事項: (2021-11-01)